{
  "id": 18973792,
  "title": "Revolution Medicines' Pancreatic Cancer Drug Nearly Doubled Survival. Is the High-Flying Stock Still a Buy?",
  "url": "https://urgent.news/2026/11/08/revolution-medicines-pancreatic-cancer-drug-nearly-doubled-survival",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-08T16:15:00.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/investing/2026/11/08/revolution-medicines-pancreatic-cancer-drug-nearly/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "Revolution Medicines' (RVMD) shares have experienced an astonishing 150% increase so far this year, thanks to the FDA's approval of Rasonque for treating metastatic pancreatic cancer. This breakthrough drug has the potential to nearly double the survival time of patients with metastatic pancreatic adenocarcinoma. The approval marks Revolution's first success and validates the company's approach to treating various RAS-addicted cancers, which are responsible for 20% to 30% of all cancers. Despite the stock's impressive performance, some investors remain cautious, with consensus analyst targets still above current trading levels. The company's pipeline includes several other phase 3 trials for various pancreatic cancer types and non-small cell lung cancer (NSCLC), further boosting its potential for growth.",
  "summary": "Revolution Medicines isn't profitable, but it has a drug with blockbuster potential.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Nasdaq Markets",
        "title": "Revolution Medicines' Pancreatic Cancer Drug Nearly Doubled Survival. Is the High-Flying Stock Still a Buy?",
        "url": "https://urgent.news/2026/11/08/revolution-medicines-pancreatic-cancer-drug-nearly-doubled-survival-18981801",
        "published": "2026-11-08T16:35:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}